Mersana Therapeutics (MRSN) Peer Comparison

$29.08

$0.00 (0.00%)

As on 06-Jan-2026 09:30EDT

Market cap

$145 Mln

Revenue (TTM)

$33 Mln

P/E Ratio

--

P/B Ratio

32

Div. Yield

0 %

Edit

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Market cap ($ Mln)	145	6,962
Revenue ($ Mln)	33	--
Net Profit ($ Mln)	-70.08	-184.74
Net Margin (%)	-211.21	--
RoE (%)	--	-65.50
Price to Earnings	--	--
Price-To-Book	32.03	16.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Operating Revenue	33.18	0.00
Cost of Revenue	0.69	128.34
Gross Profit	40.50	1.28
Operating Expenses	100.27	150.46
Operating Profit (EBIT)	-67.38	-195.46
Other Income	0.00	0.00
Profit before Tax	-70.08	-184.80
Provision for Tax	-1.22	0.00
Profit after Tax (Net Income)	-70.08	-184.74
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Shareholder's Funds	-59.54	422.39
Minority Interest	0.00	0.00
Non-Current Liabilities	78.95	0.42
Current Liabilities	43.27	95.84
Total Liabilities	144.66	214.80

Assets ($ Mln)

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Non-Current Assets	2.70	75.83
Current Assets	59.99	442.82
Total Assets	144.66	214.80
Total Debt*	2.29	1.98
Net Current Assets	16.72	346.98

Cashflow ($ Mln)

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Cash From Operating Activities	-82.34	-176.53
Cash Flow from Investing Activities	11.44	-0.13
Cash from Financing Activities	4.09	337.06
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
ROCE (%)	-154.06	-207.67
ROE (%)	-505.14	-65.50
ROA (%)	-40.77	-44.99
EBIT Margin (%)	-202.94	--
Net Margin (%)	-211.21	-13,319.76
Cash Profit Margin (%)	0.00	--

Growth Ratios

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Revenue Growth (%)	-4.76	-0.95
EBIT Growth (%)	4.06	-340.88
Net Profit Growth (%)	6.08	-50.03
EPS Growth (%)	8.07	45.89
Book Value Growth (%)	-5,686.95	53.43

Valuation Ratios

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Price / Earnings	-0.10	-1.54
Price / Book Value	-0.74	1.60
Dividend Yield (%)	--	--
EV/EBITDA	1.56	-0.43
Market Cap ($ Cr)	--	--

Solvency Ratios

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	-0.04	0.00
Current Ratio	1.39	4.62
Quick Ratio	1.39	4.62
Interest Coverage	-24.52	--

Operating Efficiency Ratios

	Mersana Therapeutics (MRSN)	Cidara Therapeutics (CDTX)
Debtors to sales (%)	0.51	132.86
Asset Turnover	0.19	0.00
Receivable days	0.00	2,569.64
Inventory Days	--	26.24
Payable days	1,306.76	15.88
Cash Conversion Cycle	--	2,580.00

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly